Julie Draper, in Alto Pass, IL - Speech-Language Pathologist

Julie Draper, is a Speech-language Pathologist based in Alto Pass, Illinois. Julie Draper is licensed to practice in Illinois (license number ) and her current practice location is 610 Lake Dr, Alto Pass, Illinois. She can be reached at her office (for appointments etc.) via phone at (618) 893-4493.

NPI number for Julie Draper is 1669595146 and her current mailing address is 610 Lake Dr, Alto Pass, Illinois. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1669595146.

Contact Information

	Julie Draper,
	610 Lake Dr, Alto Pass, IL 62905-1015
	(618) 893-4493
	Not Available

Healthcare Provider's Profile

Full Name	Julie Draper
Gender	Female
Speciality	Speech-language Pathologist
Location	610 Lake Dr, Alto Pass, Illinois
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1669595146
Provider Enumeration Date: 04/09/2007
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Julie Draper such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1669595146	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
235Z00000X	Speech-language Pathologist	(Illinois)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Julie Draper is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Julie Draper, 610 Lake Dr, Alto Pass, IL 62905-1015 Ph: (618) 893-4493	Julie Draper, 610 Lake Dr, Alto Pass, IL 62905-1015 Ph: (618) 893-4493

News Archive

First patient of U.S. phase 1 trial treated with Genticel's GTL001 candidate for HPV 16/18 infections

Genticel, a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the first patient of the U.S. phase 1 clinical trial has been vaccinated with GTL001, the company's first-in-class therapeutic vaccine candidate against HPV 16/18 infections.

Assessment tools, interconnected webs of relationships help address childhood adversity, trauma

Two new studies led by researchers at the Johns Hopkins Bloomberg School of Public Health suggest that the bevy of tools available to assess and address childhood adversity and trauma, as well as the interconnected webs of relationships among families and the providers who care for children, are key to healing the effects of these potentially life-altering circumstances.

"Soft opt-out" system may increase consent rates for organ donation after death

Research published in Anaesthesia suggests that a "soft opt-out" system may increase consent rates for organ donation after death, which could boost the number of organs available for transplantation.

Micronics to advance PanNAT system for molecular diagnosis of infectious pathogens

Micronics, Inc., a development-stage company, today announced that the Department of Defense has awarded the company an Applied Research and Technology Development Award under the U.S. Army Medical Research and Materiel Command's Polytrauma and Blast Injury project for advancement of its PanNAT system for point-of-care molecular diagnosis of infectious pathogens.

Research opens door to better treatment for common cause of diarrhea

One of the most common causes of diarrhea worldwide – accounting for millions of cases and tens of thousands of deaths, mostly of small children – is the parasiteCryptosporidium.

Julie Draper, - Speech-Language Pathologist in Alto Pass, IL